Literature DB >> 29032282

Atypical ductal hyperplasia: Our experience in the management and long term clinical follow-up in 71 patients.

Antuono Latronico1, Luca Nicosia2, Angela Faggian3, Francesca Abbate1, Silvia Penco1, Anna Bozzini1, Christine Cannataci4, Giovanni Mazzarol5, Enrico Cassano1.   

Abstract

INTRODUCTION: Atypical ductal hyperplasia (ADH) is a high-risk benign lesion found in approximately 1-10% of breast biopsies and associated with a variable incidence of carcinoma after surgical excision. The main goal of our study is to present our experience in the management and long-term follow-up of 71 patients with ADH diagnosed on breast biopsy.
MATERIALS AND METHODS: Results of 3808 breast biopsy specimens from 1 January 2000 to 31 December 2005 were analyzed to identify all biopsies which resulted in a diagnosis of ADH. The histopathological results of the 45 patients who underwent surgery were analyzed. Long-term follow-up for the remaining patients was carried out.
RESULTS: 45 of 71 (63.4%) patients with histological diagnosis of ADH on breast biopsy underwent surgery. Definitive histological results revealed invasive carcinoma in 7 cases (15.6%), high grade Ductal Carcinoma in situ (DCIS) in 10 (22.2%) patients, Lobular Carcinoma in situ (LCIS) in 4 cases (8.9%) and benign findings in 24 cases (53.3%). 12 of 71 (16.9%) patients underwent only long term follow-up; one (8,3%) of these developed invasive breast carcinoma after 6 years.
CONCLUSION: Atypical ductal hyperplasia diagnosed on breast biopsy is associated with a relatively high incidence of invasive carcinoma and high grade ductal carcinoma in situ at the time of surgical excision. Certain radiological and cytological criteria can be used to help determine which patients should forgo surgery and be followed up with good results. Long term follow-up is always crucial for patients who have not undergone surgery.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atypical ductal hyperplasia; Breast biopsy; Breast surgery; Follow up

Mesh:

Year:  2017        PMID: 29032282     DOI: 10.1016/j.breast.2017.10.003

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  4 in total

1.  Value of stereotactic 11-gauge vacuum-assisted breast biopsy in non-palpable suspicious calcifications: an eight-year single institution experience with 587 patients.

Authors:  Shiping Li; Feilin Qu; Yinlong Yang; Lei Wang; Juping Shen; Zhiming Shao
Journal:  Gland Surg       Date:  2020-10

2.  Vacuum assisted breast biopsy (VAB) excision of subcentimeter microcalcifications as an alternative to open biopsy for atypical ductal hyperplasia.

Authors:  Simone Schiaffino; Elena Massone; Licia Gristina; Piero Fregatti; Giuseppe Rescinito; Alessandro Villa; Daniele Friedman; Massimo Calabrese
Journal:  Br J Radiol       Date:  2018-02-23       Impact factor: 3.039

Review 3.  Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended?

Authors:  Marco Lucioni; Chiara Rossi; Pascal Lomoro; Francesco Ballati; Marianna Fanizza; Alberta Ferrari; Carlos A Garcia-Etienne; Emanuela Boveri; Giulia Meloni; Maria Grazia Sommaruga; Elisa Ferraris; Angioletta Lasagna; Elisabetta Bonzano; Marco Paulli; Adele Sgarella; Giuseppe Di Giulio
Journal:  Eur Radiol       Date:  2020-08-20       Impact factor: 5.315

Review 4.  Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Authors:  Christoph J Rageth; Elizabeth A M O'Flynn; Katja Pinker; Rahel A Kubik-Huch; Alexander Mundinger; Thomas Decker; Christoph Tausch; Florian Dammann; Pascal A Baltzer; Eva Maria Fallenberg; Maria P Foschini; Sophie Dellas; Michael Knauer; Caroline Malhaire; Martin Sonnenschein; Andreas Boos; Elisabeth Morris; Zsuzsanna Varga
Journal:  Breast Cancer Res Treat       Date:  2018-11-30       Impact factor: 4.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.